All In MedTech

Device Trial Radar · NCT06010563

VenusP-Valve Pivotal Study (PROTEUS STUDY)

Evaluation of the Performance of the VenusP-ValveTM System in Patients with Native RVOT Dysfunction

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 11, 2024

Primary completion

Jun 30, 2026

Study completion Aug 30, 2034

Sponsor

Lead sponsor
Venus MedTech (HangZhou) Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 24, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, multi-center, non-randomized interventional study to evaluate the safety and effectiveness of the VenusP-ValveTM System in patients with native right ventricular outflow tract (RVOT) dysfunction. Post procedure, a clinical visit will be scheduled at pre-discharge, 30 days, 6 months, 12 months, and annually thereafter to 10 years. About 60 subjects will be enrolled in this study. Data analysis will be performed after all enrolled subjects complete 6-month follow-up and the primary endpoint analysis report will be submitted to FDA for PMA approval.

Conditions

  • Pulmonary Regurgitation

Interventions

  • Transcatheter pulmonary valve implantation (TPVI)Device

    A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.

  • VenusP-ValveTM SystemDevice

    VenusP-ValveTM System consists of two components: 1. Transcatheter Pulmonary Valve (TPV) 2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue. For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV. The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of procedure or device related mortality at the 30 days follow-up visit post procedureTime frame: At 30 Days Post Procedure
  2. The rate of re-intervention and acceptable hemodynamic function at 6 Month follow-up visit post procedureTime frame: At 6 Months Post Procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Venusmedtech of America

    Irvine, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.